{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:46:50Z","timestamp":1787928410634,"version":"build-2784847793"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy has been recognized as a strategy for treating various malignant tumors. However, it has faced significant challenges in AML, primarily because myeloid blasts do not contain unique surface antigens. The preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is abnormally expressed in AML and does not exist in normal hematopoietic cells. Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML blasts, its implications in prognosis and follow-up, and its use in antigen-specific immunotherapy for AML.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1378277","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:22:28Z","timestamp":1711426948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting PRAME for acute myeloid leukemia therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Jinjun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"Bmj"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-017-0453-8","article-title":"Immunotherapy in hematologic Malignancies: past, present, and future","volume":"10","author":"Im","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/s1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-6-120","article-title":"Duplication and positive selection among hominin-specific PRAME genes","volume":"6","author":"Birtle","year":"2005","journal-title":"BMC Genomics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1101\/gr.7.3.250","article-title":"One-megabase sequence analysis of the human immunoglobulin lambda gene locus","volume":"7","author":"Kawasaki","year":"1997","journal-title":"Genome Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jsb.2006.01.016","article-title":"Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans","volume":"155","author":"McEwan","year":"2006","journal-title":"J Struct Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/366751a0","article-title":"Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats","volume":"366","author":"Kobe","year":"1993","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab1061","article-title":"AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models","volume":"50","author":"Varadi","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci92335","article-title":"A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide\/HLA-I antigens","volume":"127","author":"Chang","year":"2017","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/cancers11070984","article-title":"Cancer testis antigens and immunotherapy: where do we stand in the targeting of PRAME","volume":"11","author":"Al-Khadairi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/biolre\/ioab074","article-title":"The PRAME family of cancer testis antigens is essential for germline development and gametogenesisdagger","volume":"105","author":"Kern","year":"2021","journal-title":"Biol Reprod"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-04-4011","article-title":"Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo","volume":"65","author":"Tajeddine","year":"2005","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.03.039","article-title":"Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia","volume":"34","author":"Luetkens","year":"2010","journal-title":"Leuk Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12185-014-1593-z","article-title":"Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy","volume":"100","author":"Mitsuhashi","year":"2014","journal-title":"Int J Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000381533","article-title":"PRAME expression and its clinical relevance in hodgkin\u2019s lymphoma","volume":"134","author":"Ercolak","year":"2015","journal-title":"Acta Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149640","article-title":"Preferentially expressed antigen of melanoma prevents lung cancer metastasis","volume":"11","author":"Huang","year":"2016","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.0729","article-title":"PRAME as a potential target for immunotherapy in metastatic uveal melanoma","volume":"135","author":"Gezgin","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-017-0077-3","article-title":"Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes","volume":"7","author":"Roszik","year":"2017","journal-title":"Clin Sarcoma Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.breast.2018.08.106","article-title":"Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy","volume":"42","author":"Tessari","year":"2018","journal-title":"Breast"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402718","article-title":"The role of retinoids and retinoic acid receptors in normal hematopoiesis","volume":"16","author":"Collins","year":"2002","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-2524","article-title":"PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation\u2013a possible target for ATRA response in AML without t(15;17)","volume":"19","author":"Bullinger","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-226","article-title":"Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia","volume":"9","author":"Wadelin","year":"2010","journal-title":"Mol Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2007.05.011","article-title":"PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia","volume":"177","author":"Steinbach","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170282","article-title":"The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702518104","article-title":"A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors","volume":"104","author":"Epping","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150045","article-title":"Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia","volume":"112","author":"Quintarelli","year":"2008","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00982.x","article-title":"PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells","volume":"102","author":"van Baren","year":"1998","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-4608(01)00570-2","article-title":"Clinical implications of PRAME gene expression in childhood acute myeloid leukemia","volume":"133","author":"Steinbach","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0301-472x(00)00550-6","article-title":"Simultaneous expression of different immunogenic antigens in acute myeloid leukemia","volume":"28","author":"Greiner","year":"2000","journal-title":"Exp Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.09.004","article-title":"Measurable residual disease monitoring of SPAG6, ST18, PRAME, and XAGE1A expression in peripheral blood may detect imminent relapse in childhood acute myeloid leukemia","volume":"23","author":"Skou","year":"2021","journal-title":"J Mol Diagn"},{"key":"B39","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.09.006","article-title":"The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients","volume":"101","author":"Thongprasert","year":"2016","journal-title":"Lung Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20380","article-title":"Expression of cancer testis antigens in head and neck squamous cell carcinomas","volume":"28","author":"Figueiredo","year":"2006","journal-title":"Head Neck"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci145343","article-title":"Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma","volume":"132","author":"Takata","year":"2022","journal-title":"J Clin Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.02.031","article-title":"PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma","volume":"30","author":"Proto-Siqueira","year":"2006","journal-title":"Leuk Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200003)30:3<803::AID-IMMU803>3.3.CO;2-G","article-title":"The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells","volume":"30","author":"Pellat-Deceunynck","year":"2000","journal-title":"Eur J Immunol"},{"key":"B46","first-page":"2","article-title":"Prognostic impact of cancer\/testis antigen expression in advanced stage multiple myeloma patients","volume":"8","author":"Andrade","year":"2008","journal-title":"Cancer Immun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008304","article-title":"Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia","volume":"7","author":"Kirkey","year":"2023","journal-title":"Blood Adv"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41467-023-41994-0","article-title":"Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia","volume":"14","author":"Mumme","year":"2023","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02670.x","article-title":"Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia","volume":"112","author":"Matsushita","year":"2001","journal-title":"Br J Haematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11623","article-title":"mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies","volume":"108","author":"Greiner","year":"2004","journal-title":"Int J Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20425","article-title":"PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects","volume":"79","author":"Paydas","year":"2005","journal-title":"Am J Hematol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2006.106","article-title":"Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia","volume":"44","author":"Tajeddine","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802035933","article-title":"Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2","volume":"49","author":"Tajeddine","year":"2008","journal-title":"Vitro vivo Leuk Lymphoma"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.08.026","article-title":"Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease","volume":"33","author":"Qin","year":"2009","journal-title":"Leuk Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13214","article-title":"The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia","volume":"93","author":"Santamar\u00eda","year":"2008","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia","volume":"350","author":"Bullinger","year":"2004","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-023127","article-title":"Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches","volume":"108","author":"Greiner","year":"2006","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04982.x","article-title":"Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down\u2019s syndrome, revealing PRAME as a specific discriminating marker","volume":"125","author":"McElwaine","year":"2004","journal-title":"Br J Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(00)01112-1","article-title":"Identification of a melanoma antigen, PRAME, as a BCR\/ABL-inducible gene","volume":"466","author":"Watari","year":"2000","journal-title":"FEBS Lett"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0514-8","article-title":"Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia","volume":"87","author":"Ortmann","year":"2008","journal-title":"Ann Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22141","article-title":"Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia","volume":"86","author":"Atanackovic","year":"2011","journal-title":"Am J Hematol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/gcc.20465","article-title":"Hypomethylation of PRAME is responsible for its aberrant overexpression in human Malignancies","volume":"46","author":"Schenk","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.06.018","article-title":"Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression","volume":"42","author":"Goellner","year":"2006","journal-title":"Eur J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.04.005","article-title":"Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells","volume":"35","author":"Tanaka","year":"2011","journal-title":"Leuk Res"},{"key":"B65","article-title":"PRAME induces apoptosis and inhibits proliferation of leukemic cells in vitro and in vivo","volume":"8","author":"Xu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B66","article-title":"PRAME promotes in vitro leukemia cells death by regulating S100A4\/p53 signaling","volume":"20","author":"Xu","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2017.3951","article-title":"PRAME gene copy number variation is related to its expression in multiple myeloma","volume":"36","author":"Yang","year":"2017","journal-title":"DNA Cell Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-187724","article-title":"Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia","volume":"114","author":"Santamar\u00eda","year":"2009","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3324\/haematol.13378","article-title":"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia","volume":"94","author":"Schlenk","year":"2009","journal-title":"Results AMLSG Trial AML HD98B Haematologica"},{"key":"B70","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood-2009-04-212530","article-title":"Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias","volume":"115","author":"Ommen","year":"2010","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401652","article-title":"Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR","volume":"14","author":"Cassinat","year":"2000","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100650","article-title":"The minimal that kills: Why defining and targeting measurable residual disease is the \u201cSine Qua Non\u201d for further progress in management of acute myeloid leukemia","volume":"43","author":"Bewersdorf","year":"2020","journal-title":"Blood Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03261.x","article-title":"Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms\u2019 tumour gene WT1 at levels similar to those in leukaemia cells","volume":"116","author":"Hosen","year":"2002","journal-title":"Br J Haematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702095","article-title":"The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation","volume":"25","author":"Elmaagacli","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29583","article-title":"Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens","volume":"137","author":"Schneider","year":"2015","journal-title":"Int J Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-2552","article-title":"Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia","volume":"12","author":"Steinbach","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000035725","article-title":"Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological Malignancies","volume":"44","author":"Matsushita","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.999298","article-title":"Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR","volume":"13","author":"Stanojevic","year":"2022","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-1999","article-title":"Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia","volume":"21","author":"Steinbach","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.blre.2018.12.001","article-title":"Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era","volume":"34","author":"Liu","year":"2019","journal-title":"Blood Rev"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089565","article-title":"Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation","volume":"99","author":"Eefting","year":"2014","journal-title":"Haematologica"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07260.x","article-title":"Understanding and harnessing the graft-versus-leukaemia effect","volume":"142","author":"Barrett","year":"2008","journal-title":"Br J Haematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-144071","article-title":"Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia","volume":"113","author":"Rezvani","year":"2009","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.66","article-title":"Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant","volume":"27","author":"Weber","year":"2013","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-1905","article-title":"Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell","volume":"13","author":"Butler","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B90","first-page":"8","article-title":"Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia","volume":"3","author":"Li","year":"2003","journal-title":"Cancer Immun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1200","article-title":"Ex vivo enrichment of PRAME antigen-specific T cells for adoptive immunotherapy using CD137 activation marker selection","volume":"9","author":"Lee","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17464","article-title":"Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine","volume":"194","author":"Koukoulias","year":"2021","journal-title":"Br J Haematol"},{"key":"B93","article-title":"A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults","volume":"21","author":"LaVoy","year":"2015","journal-title":"Exerc Immunol Rev"},{"key":"B94","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.molimm.2016.07.012","article-title":"The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation","volume":"77","author":"Mohamed","year":"2016","journal-title":"Mol Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23971","article-title":"Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy","volume":"2","author":"van den Ancker","year":"2013","journal-title":"Oncoimmunology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-1066","article-title":"PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-300376","article-title":"High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells","volume":"117","author":"Quintarelli","year":"2011","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106842","article-title":"T(H)1 cytokines induce senescence in AML","volume":"117","author":"Hashimoto","year":"2022","journal-title":"Leuk Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070522","article-title":"Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine","volume":"8","author":"Yao","year":"2013","journal-title":"PloS One"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18326","article-title":"Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody","volume":"198","author":"Greiner","year":"2022","journal-title":"Br J Haematol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/cancers14081998","article-title":"T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity","volume":"14","author":"Sailer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells","volume":"28","author":"Pizzitola","year":"2014","journal-title":"vivo Leukemia"},{"key":"B104","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1084\/jem.193.1.73","article-title":"Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis","volume":"193","author":"Kessler","year":"2001","journal-title":"J Exp Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009471","article-title":"Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant","volume":"137","author":"Lulla","year":"2021","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006831","article-title":"Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT","volume":"6","author":"Kinoshita","year":"2022","journal-title":"Blood Adv"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2021.39.15_suppl.2538","article-title":"Preliminary analysis of a phase 1\/2 study of NEXI-001 donor-derived multi-antigen-specific CD8+ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT)","volume":"39","author":"Al Malki","year":"2021","journal-title":"J Clin Oncol"},{"key":"B108","unstructured":"Medigene presents final phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers2023"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000322","article-title":"WT1, PRAME, and PR3 mRNA expression in acute myeloid leukemia (AML)","volume":"43","author":"Steger","year":"2020","journal-title":"J Immunother"},{"key":"B110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3892\/ijo","article-title":"Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts","volume":"28","author":"Li","year":"2006","journal-title":"Int J Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01980-3","article-title":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","volume":"37","author":"Fl\u00f8isand","year":"2023","journal-title":"Leukemia"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1117","article-title":"Toll-like receptor 7\/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial","volume":"9","author":"Lichtenegger","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-142806","article-title":"Therapeutic cancer vaccination targeting shared tumor associated antigens in combination with azacitidine for high risk myelodysplastic syndrome - a phase I clinical trial","volume":"136","author":"Staffan","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1378277\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T04:22:36Z","timestamp":1711426956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1378277\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":113,"alternative-id":["10.3389\/fimmu.2024.1378277"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1378277","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"article-number":"1378277"}}